Clinical trials: Opioid Use Disorders
Opioid Use Disorder
A Project to Test the Efficacy and Safety of An Innovative Treatment for Opiate Use Disorders.
Investigators will test, for safety and efficacy, a novel treatment for opiate addiction that applies a 4-minute treatment of intense near infra-red light to stimulate a side of the brain that the investigators determine to be…
- Trial name
- NCT05995873
- Testing
- transcranial photobiomodulation at 810 nm at 250 mW/cm2 for 4 minutes
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- MindLight, LLC
Treatment for Opioid Use Disorder
A Study to Train a Machine Learning Algorithm for an Evaluation of the Use of Biometric Data Captured at the Wrist for the Identification of Acute Opioid Use Events and the Quantification of Opioid Withdrawal in Opioid Dependent Individuals
To train a machine learning model/algorithm for an evaluation of the use of biometric data captured at the wrist for the identification of acute opioid use events and the quantification of opioid withdrawal in opioid dependent…
- Trial name
- NCT07405398
- Testing
- Train and evaluate the accuracy and reliability of the Strength Band Platform in identifying acute opioid dosing events from time-stamped biometric data collected from wrist-worn devices.
- Where
- United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- OpiAID
Opioid Use Disorder (OUD)
A Safety Study of AZD4041 in Healthy Participants
This is a Phase 1, single-centre, randomized, double-blind, placebo-controlled, multiple ascending doses (MAD) study in healthy male and female adult participants.
- Trial name
- NCT05233085
- Testing
- AZD4041
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Opioid Use Disorder
Reward-Based Recovery Outcomes Management for Opioid Use Disorder
A randomized pilot study assessing feasibility, acceptability, and preliminary effectiveness of a reward-based recovery management platform (PROCare) designed to enhance participation in outcomes monitoring, engagement in…
- Trial name
- NCT04669249
- Testing
- PROCare
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Medical Decision Logic, Inc.
Nondependent Opioid Abuse, Episodic
Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users
The primary purpose of this study is to determine the abuse potential of EMBEDA compared to controlled release morphine when crushed and taken orally by non-dependent recreational opioid users; secondary purposes include to…
- Trial name
- NCT01380093
- Testing
- MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Pfizer
Opioid Use Disorder, Opioid Withdrawal
Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder
IBO-CARE is a single-site Phase 1/2a study evaluating the safety, tolerability, feasibility and preliminary outcomes of medically supervised ibogaine with 12 months of recovery support in adults with moderate-to-severe opioid use…
- Conditions
- Opioid Use Disorder, Opioid Withdrawal, Substance Use Disorders
- Trial name
- IBO-CARE (NCT07871877)
- Testing
- Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, My-E-Health SENTINEL Digital Monitoring and Human-Gated Escalation Platform
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Clive Michelsen
Post-Operative Pain Management
Study to Evaluate Iovera®° in Adult Patients Undergoing Total Knee Arthroplasty
Primary objective: The primary objective of this study is to evaluate postsurgical pain control, after presurgical iovera° treatment plus EXPAREL® and standardized multimodal therapy compared with presurgical sham iovera°…
- Trial name
- NCT04191031
- Testing
- ioveraº
- Where
- 7 sites in United States
- Volunteers
- 79 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Opioid Use Disorder
Single-dose, Study of RBP-6000 in Opioid Dependent Individuals
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic profile of an injection of RBP-6000.
- Trial name
- NCT02765867
- Testing
- RBP-6000
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Indivior Inc.
Opioid-use Disorder
Technology for MAT in Primary Care - Phase 1
With over 72,000 overdose deaths in 2017, of which 47,600 are attributable to opioid overdose, the opioid epidemic has become North America's most widespread behavioral public health problem.
- Trial name
- NCT05006846
- Testing
- Opioid Addiction Recovery Support Software Platform
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Q2i, LLC
Parenting, Opioid-use Disorder
Fathering In Recovery
The majority of men experiencing opioid use disorder and receiving treatment are fathers. Substance use, transitions between in-patient and out-patient treatment, and reunification as a family, all create considerable strain and…
- Conditions
- Parenting, Opioid-use Disorder, Father-Child Relations, Fathers
- Trial name
- FIR (NCT04611542)
- Testing
- Fathering In Recovery
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Opioid-use Disorder
mHealth for Patient Self-Management of Opioid Use Disorder
Twenty individuals diagnosed with opioid use disorder (OUD) will be recruited to participate in a beta test to demonstrate feasibility of using an online tool to help them better self-manage their recovery.
- Trial name
- NCT03633929
- Testing
- KIOS OUD
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Biomedical Development Corporation
Opioid Use Disorder
Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder
This is a multiple-dose study in non-treatment seeking male and female subjects with moderate to severe opioid use disorder who meet criteria from the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) to…
- Trial name
- NCT02044094
- Testing
- Buprenorphine, buprenorphine and naloxone, hydromorphone
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Indivior Inc.
Lumbar Spine Stenosis, Lumbar Spine Degeneration
OpalGenix- Personalized Postoperative Pain Management Following Lumbar Spinal Fusion and Decompression Surgery in Adults
The proposed research is an important extension of an ongoing perioperative personalized analgesia and intravenous opioid pharmacogenetic research.
- Trial name
- NCT05452694
- Where
- 3 sites in United States
- Volunteers
- 235 people
- Sponsor
- OpalGenix, Inc
Opioid Use Disorder
Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder
This is a single-center, randomized, open-label, single-dose, parallel-group study which will enroll and randomize approximately 48 subjects (to achieve 36 completers) with opioid use disorder (OUD) who are seeking treatment for…
- Trial name
- NCT02559973
- Testing
- RBP-6000, SUBOXONE Sublingual Film
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Indivior Inc.
Opioid Withdrawal (Disorder), Opioid Use Disorder
A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects
The goal of this clinical study is to evaluate the pharmacokinetic (PK), safety, and tolerability of LUCEMYRA in adolescents age ≥12 to <18 years old abruptly discontinuing opioid use.
- Trial name
- NCT06711640
- Testing
- LUCEMYRA (lofexidine) tablets
- Where
- United States
- Sponsor
- USWM, LLC (dba US WorldMeds)
Opioid-use Disorder, Opioid Dependence
Efficacy And Safety Of An Innovative Treatment Of Opiate Use Disorders
Investigators will test, for safety and efficacy, a novel treatment for opiate addiction that applies a 4-minute treatment of intense near infra-red light to stimulate a side of the brain that the investigators determine to be…
- Conditions
- Opioid-use Disorder, Opioid Dependence, Opioid Abuse
- Trial name
- NCT04340622
- Testing
- supra-luminous LED
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- MindLight, LLC
Opiate Dependence
ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids
This was a Phase 2, multicenter, randomized, double-blind pilot study in opioid-using adults to assess the presence, duration, and degree of opiate blockade as well as the safety and tolerability of Medisorb® naltrexone…
- Trial name
- NCT01218984
- Testing
- Medisorb naltrexone 75 mg, Medisorb naltrexone 150 mg, Medisorb naltrexone 300 mg
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Opioid Use Disorder
Brain Training for Substance Use Disorders
Participants play games designed to train visual attention towards natural, non-drug-related scenarios. A biofeedback loop between gameplay and an electroencephalogram (EEG) system monitors game performance and guides game…
- Trial name
- NCT06870110
- Testing
- Bias Modification Biofeedback
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Neurotype Inc.
Opioid Use Disorder, Moderate
Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy
A Phase 1, Single Dose, Open-label, Safety, Tolerability, and Pharmacokinetic Study of LYN-014 in Individuals with Opioid Use Disorder Who are Stable on Methadone Therapy
- Trial name
- NCT05251376
- Testing
- Levomethadone HCl, Methadone, Morphine Sulfate
- Sponsor
- Lyndra Inc.
Healthy Volunteer Study, Opioid-use Disorder
A Phase 1 Study Investigating the Safety, Tolerability and Pharmacokinetics of KNX100 in Healthy Volunteers
The primary objectives of this study are to evaluate the safety and tolerability of KNX100 administered orally as a single and multiple ascending doses in healthy volunteers.
- Trial name
- KTX101 (NCT04901078)
- Testing
- KNX100
- Where
- Australia
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Kinoxis Therapeutics Pty Ltd